DDInter392 DDInter1628
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Cladribine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Cladribine {u} (Compound) downregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Cladribine {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Cladribine {u} (Compound) downregulates {v} (Gene) C2CD5
C2CD5 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Cladribine {u} (Compound) upregulates {v} (Gene) BRCA1
BRCA1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Cladribine {u} (Compound) binds {v} (Gene) POLE2
POLE2 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Cladribine {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Cladribine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is associated with {v} (Gene) JAK1
JAK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Cladribine {u} (Compound) downregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is regulated by {v} (Gene) LRRK2
LRRK2 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Cladribine {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is regulated by {v} (Gene) CAMK1D
CAMK1D {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Cladribine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Cladribine (Compound) downregulates PLK1 (Gene) and PLK1 (Gene) is bound by Ruxolitinib (Compound)
Cladribine (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Cladribine (Compound) downregulates C2CD5 (Gene) and C2CD5 (Gene) is downregulated by Ruxolitinib (Compound)
Cladribine (Compound) upregulates BRCA1 (Gene) and BRCA1 (Gene) is downregulated by Ruxolitinib (Compound)
Cladribine (Compound) binds POLE2 (Gene) and POLE2 (Gene) is downregulated by Ruxolitinib (Compound)
Cladribine (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Cladribine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is associated with JAK1 (Gene) and JAK1 (Gene) is bound by Ruxolitinib (Compound)
Cladribine (Compound) downregulates PLK1 (Gene) and PLK1 (Gene) is regulated by LRRK2 (Gene) and LRRK2 (Gene) is bound by Ruxolitinib (Compound)
Cladribine (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is regulated by CAMK1D (Gene) and CAMK1D (Gene) is bound by Ruxolitinib (Compound)